Centene Corp (CNC)
UndervaluedFundamental
44
Price
$70.17
Market Cap
$34.70B
Part 1 · What the company is worth
Overview
Centene operates as a major healthcare insurer serving primarily government-sponsored programs and vulnerable populations. The company manages healthcare for approximately 28.6 million members across Medicaid, Medicare Advantage, TRICARE, Marketplace insurance, and commercial plans. It operates through a decentralized local model with teams in 30 states for Medicaid and 29 states for Marketplace products, emphasizing culturally sensitive service delivery for low-income, medically complex, and dual-eligible beneficiaries.
How it makes money
Centene generates revenue primarily through premiums received from government programs: Medicaid managed care capitated rates, Medicare Advantage premiums, TRICARE reimbursement, and Marketplace insurance premiums supplemented by federal subsidies. Additional revenue comes from prescription drug plans contracted with CMS, specialty services (pharmacy management, behavioral health, vision and dental), and commercial health insurance offerings. The company earns revenue based on member enrollment and per-member per-month rates negotiated with state and federal payors.
Revenue by segment
Medicaid managed care plans serving low-income and vulnerable populations across 30 states with approximately 13 million members. This segment represents the company's largest business line, offering comprehensive healthcare coverage for eligible individuals and families.
Commercial health insurance plans for employers and individuals, including self-funded administrative services offerings. This segment serves approximately 4.4 million members through a mix of fully insured and self-funded arrangements.
Medicare Advantage plans serving seniors aged 65 and older, including prescription drug plans and dual-eligible programs. The company has approximately 1.1 million Medicare members and benefits from positioning to serve dual-eligible beneficiaries facing CMS integration requirements by 2030.
Other revenue including Marketplace insurance plans sold through the federally facilitated and state exchanges with subsidies from advanced premium tax credits, TRICARE military healthcare, and specialty services such as pharmacy management and behavioral health offerings.
Competitive moat
Scale · NarrowCentene's scale advantage derives from being the largest Medicaid insurer (30 states) and largest Marketplace carrier (29 states), giving it negotiating power with providers and states, and enabling investment in technology and care management. However, the moat is narrow because government payors can cut reimbursement rates unilaterally, Medicaid enrollment is policy-dependent, and competitors can enter markets. The company's 40+ years of expertise serving complex low-income populations and its local operating model provide intangible advantages, but these are not sufficient to create a wide competitive moat given regulatory and political risks.
What drives demand
DefensiveMedicaid demand is relatively defensive because it covers low-income and vulnerable populations who maintain healthcare needs regardless of economic cycles. However, total Medicaid enrollment depends on state policy decisions about eligibility and expansion, which can vary. Medicare Advantage and Marketplace demand are also generally non-cyclical since seniors and subsidized consumers continue seeking coverage in recessions. The company's earnings can fluctuate based on medical utilization rates and severity of illness, which may vary by economic conditions, but demand for coverage itself remains stable.
Key risks
- Medical Cost Management — Failure to accurately estimate and price medical expenses or effectively manage medical costs could materially impact profitability. The company's earnings depend on the accuracy of its actuarial pricing and its ability to control medical utilization and costs relative to premium revenues.
- Government Reimbursement Rate Risk — Centene derives significant revenue from government programs (Medicaid, Medicare, TRICARE). Government payors can unilaterally reduce reimbursement rates, modify program rules, or change rate-setting methodologies, materially impacting profitability. Policy changes or budget constraints at federal or state levels could reduce rates across all three lines of business.
- Marketplace Subsidy Dependence — Centene's Marketplace business depends on federal advanced premium tax credits that subsidize consumer premiums. These enhanced subsidies could expire without congressional renewal, making coverage unaffordable for many members and potentially causing enrollment declines and revenue loss.
- Customer Concentration — Florida and New York Medicaid contracts each represent approximately 10% or more of consolidated Medicaid premium revenues. Loss or significant rate reduction of either contract would materially impact consolidated results. Additionally, dependence on government payors (Medicaid, Medicare, TRICARE) creates concentration risk across the portfolio.
- Medicaid Disenrollment Risk — Following the expiration of Medicaid continuous enrollment provisions during the Public Health Emergency, states have conducted redeterminations of eligibility. Millions of members have been disenrolled, reducing premium revenues. Centene cannot control state eligibility determinations or re-enrollment timing.
- Regulatory and Political Uncertainty — Changes to the Affordable Care Act, Medicaid expansion, or Medicare Advantage reimbursement policies could materially affect the company's business. Regulatory investigations or audits by states regarding compliance or billing practices could result in penalties, rate reductions, or contract termination.
- Debt and Financial Leverage — Centene maintains substantial indebtedness of $23.1 billion in senior notes outstanding as of year-end 2024. High leverage constrains financial flexibility and increases financial risk, particularly if operating earnings decline or if market conditions worsen.
- Cybersecurity and Systems Integration — Centene relies on complex information systems for claims processing, payment management, and regulatory compliance. Data breaches, system failures, or failed integrations following acquisitions could disrupt operations, result in financial losses, incur remediation costs, or trigger regulatory penalties.
Customer concentration
Top customers account for 20% of revenue
Florida and New York Medicaid contracts each represent approximately 10% or more of consolidated Medicaid premium revenues, meaning the top two customers account for approximately 20% of Medicaid revenues. Beyond these two states, Centene has significant government payors including other state Medicaid programs, Medicare, and TRICARE. The overall customer base is concentrated on government programs: Medicaid, Medicare, and TRICARE together represent the vast majority of revenue, creating dependence on government reimbursement policy.
The case for
Buyers argue that Centene is well-positioned as the dominant Medicaid and Marketplace insurer with proven execution across complex government programs. The company benefits from approximately 28.6 million members and scale advantages that support margin expansion through medical cost management and operational efficiency. The dual-eligible opportunity is compelling: Centene can serve 12+ million dual-eligible beneficiaries and is positioned to benefit from CMS integration requirements by 2030, which will drive higher Medicare revenues. The company has demonstrated strong earnings growth (adjusted EPS of $7.17 in 2024, up from $6.68 in 2023) and operates in a defensive healthcare sector with steady, policy-driven demand for government-sponsored coverage. Its local operating model and deep expertise in managing vulnerable populations create barriers to entry for competitors.
The case against
Sellers fear that Centene faces existential pressure from government rate cuts and policy uncertainty. With 62% of revenue from Medicaid, the company is highly exposed to state budget pressures and political changes that can unilaterally reduce payment rates. The enhanced Marketplace subsidies could expire without renewal, eliminating the economics that made the Marketplace profitable. Florida and New York represent 20% of Medicaid revenues, creating dangerous concentration risk. Post-PHE Medicaid redeterminations have already reduced enrollment, and states may not re-expand eligibility to previous levels, creating a structural revenue headwind. The company carries $23.1 billion in debt, constraining flexibility to weather downturns. Competitors with greater scale (UnitedHealth, Anthem) can cross-subsidize Medicaid with other business lines, while Centene is heavily dependent on government rates. Medical cost management remains unpredictable—utilization trends and medical inflation can quickly erode margins. Regulatory investigations and compliance risks pose ongoing threats to profitability.
Generated with artificial intelligence on September 21, 2026, shared with all users
Direct competitors
Who this company fights with for the same customers
Generated with artificial intelligence on September 18, 2026, shared with all users
Elevance is the second-largest Medicaid managed care operator after Centene and also sells marketplace plans under its Anthem brands, so the two compete for the same state contracts and the same individual enrollees.
UnitedHealth's community and state business is one of the Big Five Medicaid plans and it has the widest ACA marketplace footprint of any insurer, overlapping Centene's Medicaid and Ambetter lines in most states.
Through Aetna, CVS Health is one of the five largest Medicaid managed care companies and a direct rival in Medicare Advantage and dual-eligible plans, the same government-funded members Centene serves.
Humana competes with Centene's Wellcare brand for Medicare Advantage and Part D members and bids for the same state Medicaid contracts, though it is far more concentrated on seniors.
Molina is Centene's closest business twin: both build their revenue on state Medicaid contracts and ACA marketplace plans for low-income members, and they bid against each other in the same state procurements.
Oscar sells almost exclusively ACA marketplace plans in twenty states and is the main challenger to Ambetter, Centene's individual-exchange brand.
Balance Sheet & Liquidity
Revenue
$178.66B
Trailing 12 months (through 6/30/2026)
Net Income
$-5.10B
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$4.32B
Total Equity
$19.95B
Total Liabilities
$56.69B
Current Ratio
1.15
Interest Coverage
8.61
Debt/EBITDA
-
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$152.80
Current Price
$70.17
Margin of Safety
+54.1%
Fair Value Range
$99.32 - $206.28
Spread across the valuation methods used, not a statistically calibrated confidence interval.
Estimation Methods
Valuation Metrics
P/E Ratio
-
ROE
-33.4%
P/B Ratio
1.54
P/FCF
3.87
Gross Margin
9.1%
ROIC
-10.5%
Profitability Radar
Value Creation (Economic Moat)
ROIC
-10.5%
WACC
8.2%
ROIC − WACC
-18.8 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (11)
- Price CAGR 9.52%
- P/FCF 3.87
- P/B ratio 1.54
- Debt/equity ratio
- Positive free cash flow
- CapEx intensity
- Current ratio
- Interest coverage
- Revenue growth 5Y 24.5%
- Earnings surprise, average 161.0%
- Share dilution -5.8%
Failed (10)
- EPS shows upward trend
- ROIC -10.5%
- Gross margin 9.1%
- Operating margin -3.2%
- Return on tangible assets
- Low reliance on intangibles
- DCF valuation (Fairly Valued)
- ROE -24.0%
- Net margin trend -2.9% vs 1.3%
- Piotroski F-Score 4/9
Unavailable (5)
- Dividend payout –
- Debt/EBITDA
- Price below Graham Number
- PEG ratio (needs P/E > 0 and growth > 0)
- Earnings quality (operating cash flow / net income)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
Low quality: investigate accounting
Share Dilution
Buying back shares. Shareholder friendly
Institutional Holdings
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Ms. Sarah M. London | CEO & Director | 44 |
| Mr. Andrew Lynn Asher | Executive VP & CFO | 56 |
| Ms. Susan R. Smith | Chief Operating Officer | 49 |
| Mr. Christopher Andrew Koster | Executive VP, General Counsel & Secretary | 60 |
| Ms. Tanya M. McNally | Senior VP & Chief People Officer | 51 |
| Mr. Theodore Joseph Pienkos | Corporate Controller & Chief Accounting Officer | 43 |
| Mr. Bradley Bolivar | Chief Information Officer | - |
| Ms. Jennifer Lynch Gilligan | Senior Vice President of Investor Relations | - |
| Ms. Ashlee Knuckey | Chief Risk, Ethics & Compliance Officer | - |
| Sara Garland | Chief Communications Officer | - |
Audit Risk
2
Board Risk
2
Compensation Risk
5
Shareholder Rights Risk
1
Documents
- View document
Annual Report (10-K)
A yearly overview of the business, its financial results, and the risks it faces.
Filed on 2026-02-17
- View document
Quarterly Report (10-Q)
A snapshot of financial performance for the most recent three-month period.
Filed on 2026-07-28
- View document
Current Report (8-K)
An announcement of a major event, such as a leadership change or big news.
Filed on 2026-10-08
via SEC EDGAR
Income History
via SEC EDGAR
Part 2 · The price and its context
This part shows how the price has behaved, not whether the company is worth owning. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Market Reaction Profile
How much CNC moves, measured on its daily prices.
More volatile than 46% of the tracked stocks (90-day volatility).
- Volatility 30d
- 31.2%
- Volatility 90d
- 34.8%
- Beta vs S&P 500 (1y)
- 0.29Correlation 0.08
- Max drawdown (12m)
- -32.7%
- ATR (14d, % of price)
- 3.08%
Earnings reactions
How CNC moved around its past quarterly results.
Next earnings release
Oct 27, 2026 · In 3 days · Before the open
EPS estimate: 0.10Revenue estimate: $46.9B
What usually happens
- Over the last 12 releases the stock moved a median of 4.8% the next day, up or down.
- Next-day moves: up 6, down 6 (out of 12).
- Of the 4 releases that beat estimates, the stock fell the next day after 2.
Release history
| Date | When | EPS est. | EPS actual | Surprise | Gap | 1 day | 5 days |
|---|---|---|---|---|---|---|---|
| Jul 27, 2026 | After the close | 1.10 | 2.51 | +129.0% | -7.1% | -0.3% | -0.5% |
| Apr 28, 2026 | Before the open | 2.15 | 3.37 | +56.4% | +3.0% | +14.0% | +23.1% |
| Feb 6, 2026 | Before the open | -1.24 | -1.19 | +3.7% | -6.7% | -3.7% | -1.9% |
| Oct 29, 2025 | Before the open | -0.14 | 0.50 | +454.9% | +10.3% | +12.5% | +8.8% |
| Jul 25, 2025 | Before the open | n/a | n/a | n/a | +1.4% | +6.1% | -2.6% |
| Apr 25, 2025 | Before the open | n/a | n/a | n/a | -5.2% | -6.3% | -3.5% |
| Feb 3, 2025 | After the close | n/a | n/a | n/a | -7.1% | -5.4% | -9.1% |
| Oct 24, 2024 | After the close | n/a | n/a | n/a | +13.6% | +4.2% | +1.0% |
| Jul 25, 2024 | After the close | n/a | n/a | n/a | +3.0% | +8.5% | +15.6% |
| Apr 25, 2024 | After the close | n/a | n/a | n/a | -2.3% | -2.2% | -1.8% |
| Feb 5, 2024 | After the close | n/a | n/a | n/a | -0.4% | +1.1% | +5.2% |
| Oct 23, 2023 | After the close | n/a | n/a | n/a | +2.4% | -1.7% | -4.1% |
Release dates from SEC 8-K filings.
Updated 10/24/2026
Historical statistics for educational purposes only. They are not forecasts and not investment advice.
Price reaction to the news
Latest news on CNC and what the price did next.
- 7/28/2026PositiveCentene Boosts Guidance, Reports Favorable Medical Costs
- +1 day
- -0.5%
- +3 days
- -5.4%
- 6/16/2026NegativeMembership Slump Forces Health Giant Centene Into Staff Buyouts: Report
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
- 3/15/2026NegativeCentene, Paramount Skydance, And Ulta Beauty Are Among Top 10 Large Cap Losers Last Week (March 9-March 13): Are the Others in Your Portfolio?
- +1 day
- -0.1%
- +3 days
- +5.1%
- 3/10/2026NegativeObamacare enrollment is plunging as costs soar, pushing down stocks like Centene
Published while the US market was open: the move of that day cannot be split into before and after the news, so no figure is shown.
Return of the stock minus return of SPY over the same days. A news item close to a price move did not necessarily cause it. Historical data for educational purposes only, not investment advice.
Latest News
Recent headlines for CNC.
- 7/28/2026POSITIVECentene Boosts Guidance, Reports Favorable Medical Costs
Centene Corporation has raised its annual profit guidance, signaling strong performance in the second quarter. The health insurer's improved outlook comes amid expectations that it can successfully navigate evolving government policies impacting the sector. This upward revision suggests robust operational execution and potentially better-than-anticipated medical cost management, which are key drivers for profitability in the health insurance industry. Investors will likely view this as a positive indicator of the company's resilience and future earnings potential.
- 6/18/2026NEUTRALIf You Invested $100 In Centene Stock 20 Years Ago, You Would Have This Much Today
An investment of $100 in Centene Corporation (CNC) stock twenty years ago would have yielded a significant return, though the exact figure is not provided in this summary. The article likely details the historical performance of Centene, a major managed care organization, over the past two decades. Investors considering Centene should analyze its long-term growth trajectory, market position within the healthcare sector, and any significant strategic shifts or regulatory challenges it has faced during this period to understand the drivers of its past performance and future potential.
- 6/16/2026NEGATIVEMembership Slump Forces Health Giant Centene Into Staff Buyouts: Report
Centene Corporation is implementing a significant cost-cutting initiative, offering voluntary buyouts to employees due to a notable decline in health plan enrollment. This move signals financial pressure and a strategic pivot to reduce operational expenses. Investors should monitor the effectiveness of these cost-saving measures and the company's ability to stabilize or grow its membership base in the coming quarters. The success of this plan will be crucial for future profitability and stock performance.
- 3/25/2026NEUTRALThe youngest-ever female Fortune 500 CEO is reinventing the largest Medicaid insurer amid funding cuts and rising costs
The article highlights the leadership of the youngest-ever female CEO at a Fortune 500 company, who is navigating Centene Corporation, a major Medicaid insurer, through a challenging environment of funding cuts and rising healthcare costs. While the article focuses on the CEO's strategic initiatives and the company's resilience, it does not provide specific financial performance data or forward-looking guidance that would directly impact stock valuation. Investors will be watching for how these strategies translate into tangible financial results in upcoming quarters.
- 3/15/2026NEGATIVECentene, Paramount Skydance, And Ulta Beauty Are Among Top 10 Large Cap Losers Last Week (March 9-March 13): Are the Others in Your Portfolio?
Centene Corporation was among the top 10 large-cap decliners last week, with its stock price falling significantly. The broader market saw healthcare, media, beauty, and tech stocks leading the downturn. This decline was attributed to a combination of factors including earnings misses, weak forward-looking guidance provided by companies, downward analyst revisions, and challenging financing conditions. Investors are advised to monitor these headwinds closely as they impact sentiment and stock performance across various sectors.
- 3/10/2026NEGATIVEObamacare enrollment is plunging as costs soar, pushing down stocks like Centene
Centene Corporation's stock is facing pressure as enrollment in the Affordable Care Act (ACA), also known as Obamacare, plummets. Soaring costs associated with the ACA are making health insurance plans less attractive, leading to a decline in policyholders. This trend directly impacts health insurers like Centene, which derive a significant portion of their revenue from ACA-compliant plans. The decrease in enrollment suggests lower premium revenues and potentially higher per-member costs for insurers, signaling a challenging financial outlook for the company and potentially others in the managed care sector.